Monday, 16 November 2026Follow on 𝕏

Markets Page 2

Markets

Four Pharma Franchises Stumble Despite Blockbuster Status

A drug generating more than $1bn in quarterly sales might ordinarily be cause for celebration. But when Alnylam Pharmaceuticals (ALNY) reported $1.01bn in second-quarter Amvuttra revenues — fractionally below published consensus estimates…